• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Definitive Healthcare Corp.

    2/27/25 4:46:58 PM ET
    $DH
    Computer Software: Prepackaged Software
    Technology
    Get the next $DH alert in real time by email
    S-8 1 dh-20250227.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 27, 2025

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM S–8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    Definitive Healthcare Corp.

    (Exact name of registrant as specified in its charter)

     

     

     

     

    Delaware

    81-3988281

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

    492 Old Connecticut Path, Suite 401

    Framingham, MA

    01701

    (Address of Principal Executive Offices)

    (Zip Code)

    Definitive Healthcare Corp. 2021 Equity Incentive Plan

    Definitive Healthcare Corp. 2023 Inducement Plan

    (Full Title of Plans)

    Matthew W. Ruderman

    Chief Legal Officer

    492 Old Connecticut Path, Suite 401

    Framingham, MA 01701

    (508) 720-4224

    (Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)

     

     

     

    Copies to:

    Jean Park

    Julia Boesch

    Cooley LLP

    55 Hudson Yards

    New York, NY 10001

    (212) 479-6000

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☒

     

     

     

     

    Non-accelerated filer

    ☐

    Smaller reporting company

    ☐

     

     

     

     

     

     

    Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


     

    EXPLANATORY NOTE

    This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which Registration Statements of Definitive Healthcare Corp. (the “Registrant”) on Form S-8 relating to the same employee benefit plan are effective. Pursuant to General Instruction E of Form S-8, the Registrant is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register (i) 5,697,677 additional shares of its Class A Common Stock, par value $0.001 per share (“Common Stock”), that were automatically added to the shares authorized for issuance under the Registrant’s 2021 Equity Incentive Plan (“2021 Plan”) and (ii) 2,117,650 additional shares of its Common Stock that were added to the shares authorized for issuance under the Registrant’s 2023 Inducement Plan (“2023 Inducement Plan”) as inducement grants under Nasdaq Listing Rule 5635(c)(4) pursuant to an amendment and restatement of the 2023 Inducement Plan approved by the Human Capital Management and Compensation Committee of the Board of Directors of the Registrant.

    The Registrant previously registered shares of its Common Stock for issuance under the (i) 2021 Plan under Registration Statements on Form S-8 filed with the Commission on September 14, 2021 (File No. 333-259535), February 27, 2023 (File No. 333-270059) and February 29, 2024 (File No. 333-277492) (collectively, the “Prior 2021 Plan Registration Statements”) and (ii) 2023 Inducement Plan under Registration Statements on Form S-8 filed with the Commission on September 6, 2023 (File No. 333-274370) and June 12, 2024 (File No. 333-280140) (together with the “Prior 2021 Plan Registration Statements,” the “Prior Registration Statements”). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Prior Registration Statements.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents, which have been filed with the Commission by the Registrant, pursuant to the Securities Act, and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as applicable, are hereby incorporated by reference in, and shall be deemed to be a part of, this Registration Statement:

    (a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 27, 2025, which includes audited financial statements for the Registrant’s latest fiscal year.

    (b) The Registrant’s Current Reports on Form 8-K, filed with the Commission on January 16, 2025 and on February 27, 2025 (solely with regard to Item 5.02 and the exhibit that relates to such item).

    (c) The description of the Common Stock contained in the Registrant’s Registration Statement on Form 8-A filed on September 15, 2021 (File No. 001-40815) under the Exchange Act, including any amendment or report filed for the purpose of updating such description, including Exhibit 4.1 of the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the Commission on March 15, 2022, including any amendment or report filed for the purpose of updating such description.

    (d) All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    1


     

    Item 8. Exhibits.

    Exhibit Index

     

     

     

    Exhibit
    No.

    Description

     

     

     4.1

    Amended and Restated Certificate of Incorporation of Definitive Healthcare Corp. (incorporated by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q (File No. 001-40815) filed with the SEC on November 8, 2021).

     

     

     4.2

    Amended and Restated Bylaws of Definitive Healthcare Corp. (incorporated by reference to Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q (File No. 001-40815) filed with the SEC on November 8, 2021).

     

     

     5.1*

    Legal Opinion of Cooley LLP.

     

     

    23.1*

    Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm

     

     

    23.2*

    Consent of Cooley LLP (included in Exhibit No. 5.1).

     

     

    24.1*

    Power of Attorney (included on signature page to this Registration Statement).

     

     

    99.1

     

    The Definitive Healthcare Corp. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.12 of the Registrant’s Annual Report on Form 10-K (File No. 001-40815) filed with the SEC on March 15, 2022).

    99.2

    The Amended and Restated Definitive Healthcare Corp. 2023 Inducement Plan (incorporated by reference to Exhibit 10.29 of the Registrant’s Annual Report on Form 10-K (File No. 001-40815) filed with the SEC on February 27, 2025).

     

     

    107*

    Filing Fee Table.

    *

    Filed herewith

    2


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Framingham, Commonwealth of Massachusetts, on February 27, 2025.

     

     

     

    DEFINITIVE HEALTHCARE CORP.

     

     

    By:

    /s/ Richard Booth

    Name:

    Richard Booth

    Title:

    Chief Financial Officer

    KNOW ALL PERSONS BY THESE PRESENTS, that each of the undersigned constitutes and appoints each of Kevin Coop and Richard Booth, or any of them, each acting alone, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign this Registration Statement on Form S-8 (including all pre-effective and post-effective amendments and registration statements filed pursuant to Rule 462(b) under the Securities Act of 1933), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, each acting alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that any such attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Name

    Title

    Date

    /s/ Kevin Coop

    Chief Executive Officer (Principal Executive Officer) and Director

    February 27, 2025

    Kevin Coop

    /s/ Richard Booth

    Chief Financial Officer (Principal Financial Officer and Accounting Officer)

    February 27, 2025

    Richard Booth

     

     

     

     

     

    /s/ Jason Krantz

     

    Executive Chairman

     

    February 27, 2025

    Jason Krantz

     

     

     

     

     

     

     

     

     

    /s/ Sastry Chilukuri

     

    Director

     

    February 27, 2025

    Sastry Chilukuri

     

     

     

     

     

    /s/ Chris Egan

    Director

    February 27, 2025

    Chris Egan

    /s/ Samuel A. Hamood

    Director

    February 27, 2025

    Samuel A. Hamood

    /s/ Jeff Haywood

    Director

    February 27, 2025

    Jeff Haywood

    /s/ Jill Larsen

    Director

    February 27, 2025

    Jill Larsen

    /s/ Scott Stephenson

    Director

    February 27, 2025

    Scott Stephenson

    /s/ Kathleen A. Winters

    Director

    February 27, 2025

    Kathleen A. Winters

     

     

     

     

     

    /s/ Lauren Young

     

    Director

     

    February 27, 2025

    Lauren Young

     

     

     

     

     

    3


    Get the next $DH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DH

    DatePrice TargetRatingAnalyst
    5/9/2025Buy → Neutral
    BTIG Research
    1/13/2025$4.00Equal Weight → Underweight
    Barclays
    12/20/2024$5.00Equal-Weight
    Stephens
    9/17/2024$7.00Buy
    BTIG Research
    7/31/2024$7.00 → $5.00Neutral → Underweight
    JP Morgan
    5/8/2024$11.50 → $9.00Overweight → Equal-Weight
    Morgan Stanley
    1/17/2024Buy → Hold
    Needham
    1/5/2024Buy → Hold
    Canaccord Genuity
    More analyst ratings

    $DH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Definitive Healthcare Corp.

      SC 13G - Definitive Healthcare Corp. (0001861795) (Subject)

      11/12/24 11:54:03 AM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G filed by Definitive Healthcare Corp.

      SC 13G - Definitive Healthcare Corp. (0001861795) (Subject)

      10/3/24 9:08:57 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G/A filed by Definitive Healthcare Corp. (Amendment)

      SC 13G/A - Definitive Healthcare Corp. (0001861795) (Subject)

      2/14/24 4:00:33 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology

    $DH
    Leadership Updates

    Live Leadership Updates

    See more
    • Definitive Healthcare Appoints Kevin Coop as CEO for Next Phase of Company's Growth

      FRAMINGHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that its Board of Directors has appointed Kevin Coop as the Company's next Chief Executive Officer and as a member of the Board of Directors, each effective June 24, 2024. Mr. Coop succeeds Jason Krantz, founder and Executive Chairman, who has been serving as Interim CEO since January 2024. Mr. Krantz will continue to serve on the Board of Directors as Executive Chairman after the CEO transition. "Kevin is an outstanding leader. He has deep, hands-on experience with data-focused businesses and has a

      5/28/24 8:00:00 AM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Established Executive and Milwaukee Business Leader Jim Emling Joins VBA as Executive Chair of the Board of Directors

      Jim Emling, the CEO of Datassential and former long-time president of Milwaukee-based Zywave, has been appointed Executive Chair of the Board of Directors at VBA, the company announced today. "We are delighted to welcome Jim officially to VBA as the Executive Chair," said Michael Clayton, the company's President and CEO. "Jim and I have worked closely together over the last 3 months and his decades of experience scaling high growth software companies combined with his strong ties to the Milwaukee technology sector will be tremendous assets to VBA as we enter our next phase of growth." Emling has deep roots in the Milwaukee technology community. He was the founding CTO of Zywave and serv

      11/28/23 5:00:00 PM ET
      $DH
      $GDRX
      Computer Software: Prepackaged Software
      Technology
      EDP Services
    • Definitive Healthcare Names Carrie Lazorchak as Chief Revenue Officer

      FRAMINGHAM, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that Carrie Lazorchak has been named Chief Revenue Officer, effective November 1, 2023. "I am thrilled to welcome Carrie Lazorchak to Definitive Healthcare as our new Chief Revenue Officer," said Robert Musslewhite, Chief Executive Officer of Definitive Healthcare. "Carrie is a fantastic fit for Definitive Healthcare. Her values and her deep belief in the power of humble collaboration make her a perfect match for our culture. Carrie brings a wealth of experience selling Software as a Service to both enterprise accounts and

      10/5/23 4:05:00 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology

    $DH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF FINANCIAL OFFICER Booth Richard Douglas covered exercise/tax liability with 7,873 shares, decreasing direct ownership by 1% to 652,630 units (SEC Form 4)

      4 - Definitive Healthcare Corp. (0001861795) (Issuer)

      5/5/25 4:30:10 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • EXECUTIVE CHAIRMAN Krantz Jason Ronald covered exercise/tax liability with 18,795 shares, decreasing direct ownership by 2% to 1,106,362 units (SEC Form 4)

      4 - Definitive Healthcare Corp. (0001861795) (Issuer)

      5/5/25 4:30:14 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • CHIEF OPERATING OFFICER Shamsuddin Kate Marie covered exercise/tax liability with 4,595 shares, decreasing direct ownership by 0.65% to 699,902 units (SEC Form 4)

      4 - Definitive Healthcare Corp. (0001861795) (Issuer)

      5/5/25 4:30:11 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology

    $DH
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $DH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2025

      FRAMINGHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended March 31, 2025.  First Quarter 2025 Financial Highlights: Revenue was $59.2 million, a decrease of 7% from $63.5 million in Q1 2024. Net Loss, inclusive of goodwill impairment charges of $176.5 million, was $(155.1) million, or (262)% of revenue, compared to $(12.7) million or (20)% of revenue in Q1 2024.  Adjusted Net Income was $7.0 million, compared to $13.0 million in Q1 2024.   Adjusted EBITDA was $14.7 million, or 25% of revenue, compar

      5/8/25 4:05:00 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Definitive Healthcare Announces Timing of Its First Quarter 2025 Financial Results Conference Call and Webcast

      FRAMINGHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its first quarter ended March 31, 2025, on Thursday, May 8, 2025 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244 (international). Shortly

      4/24/25 4:05:00 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Definitive Healthcare Corp. reports inducement grants under Nasdaq Listing Rule 5635(c)(4)

      FRAMINGHAM, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that in connection with the hiring of one senior leader, the Human Capital Management and Compensation Committee (the "Committee") of Definitive Healthcare's Board of Directors granted inducement awards. The Committee granted Jeff Moyer, Definitive Healthcare's new SVP of Growth and Sales Operations, an inducement award consisting of 364,432 time-based restricted stock units ("RSUs"), effective April 3, 2025. These awards were individually negotiated and granted as an inducement material to Mr. Moyer's respective commencement of

      4/4/25 8:00:00 AM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Definitive Healthcare downgraded by BTIG Research

      BTIG Research downgraded Definitive Healthcare from Buy to Neutral

      5/9/25 8:41:31 AM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Definitive Healthcare downgraded by Barclays with a new price target

      Barclays downgraded Definitive Healthcare from Equal Weight to Underweight and set a new price target of $4.00

      1/13/25 7:41:23 AM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Stephens initiated coverage on Definitive Healthcare with a new price target

      Stephens initiated coverage of Definitive Healthcare with a rating of Equal-Weight and set a new price target of $5.00

      12/20/24 7:31:03 AM ET
      $DH
      Computer Software: Prepackaged Software
      Technology

    $DH
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Definitive Healthcare Corp.

      SCHEDULE 13G/A - Definitive Healthcare Corp. (0001861795) (Subject)

      5/15/25 4:36:54 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SCHEDULE 13G filed by Definitive Healthcare Corp.

      SCHEDULE 13G - Definitive Healthcare Corp. (0001861795) (Subject)

      5/9/25 12:25:52 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 10-Q filed by Definitive Healthcare Corp.

      10-Q - Definitive Healthcare Corp. (0001861795) (Filer)

      5/8/25 4:22:09 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology

    $DH
    Financials

    Live finance-specific insights

    See more
    • Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2025

      FRAMINGHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended March 31, 2025.  First Quarter 2025 Financial Highlights: Revenue was $59.2 million, a decrease of 7% from $63.5 million in Q1 2024. Net Loss, inclusive of goodwill impairment charges of $176.5 million, was $(155.1) million, or (262)% of revenue, compared to $(12.7) million or (20)% of revenue in Q1 2024.  Adjusted Net Income was $7.0 million, compared to $13.0 million in Q1 2024.   Adjusted EBITDA was $14.7 million, or 25% of revenue, compar

      5/8/25 4:05:00 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Definitive Healthcare Announces Timing of Its First Quarter 2025 Financial Results Conference Call and Webcast

      FRAMINGHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its first quarter ended March 31, 2025, on Thursday, May 8, 2025 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244 (international). Shortly

      4/24/25 4:05:00 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology
    • Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2024

      FRAMINGHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter and full year ended December 31, 2024.  Fourth Quarter 2024 Financial Highlights: Revenue was $62.3 million, a decrease of 6% from $65.9 million in Q4 2023. Net Loss, inclusive of goodwill impairment charges of $97.1 million, was $(84.7) million, or (136)% of revenue, compared to $(13.4) million or (20)% of revenue in Q4 2023.  Adjusted Net Income was $12.6 million, compared to $10.6 million in Q4 2023.   Adjusted EBITDA was $17.5 million, or 28%

      2/27/25 4:05:53 PM ET
      $DH
      Computer Software: Prepackaged Software
      Technology